A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors

Phase 1 Active not recruiting 30 enrolled Suzhou Forlong Biotechnology Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, open-label, multicenter clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of FL115 administered as monotherapy in subjects with unresectable locally advanced or metastatic solid tumors. The study consists of a dose escalation phase followed by a dose expansion phase to further characterize the safety profile and clinical activity at the recommended dose level.

Timeline

Start: 2024-05-30
Primary completion: 2026-06-01
Completion: 2026-08-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FL115	Protein / enzyme biologic	—	—

Indications

No indication recorded.